Cannabinoids May Offer Modest Short-Term Relief for Neuropathic Pain

A 2024 systematic review found that some cannabinoid products may reduce neuropathic pain in the short term, but the evidence is based on only five small randomized, placebo-controlled trials. The findings are encouraging, particularly for topical cannabidiol (CBD), yet they do not establish cannabis as a broadly effective or risk-free treatment for chronic nerve pain.

Published in Cureus, the review examined research published between January 2000 and August 2024. The authors searched more than 125,000 records but ultimately included five trials involving cannabinoid treatments for neuropathic pain or fibromyalgia. The studies tested different products, doses, and delivery methods, including sublingual THC, inhaled THC, cannabis oil, and topical CBD.

The review reported that cannabinoid-treated participants experienced greater pain relief than placebo-treated participants on a visual analog scale—33% compared with 15%. However, the included studies were small and varied substantially in design, meaning the percentage should not be interpreted as a universal estimate of how much pain relief patients can expect. The review was also primarily a systematic narrative assessment rather than a large pooled meta-analysis.

One of the most notable findings came from a 2020 trial of topical CBD in 29 people with symptomatic peripheral neuropathy. Participants applied a CBD cream four times daily for four weeks. Compared with placebo, the CBD group reported reductions in sharp pain, intense pain, and itching. No adverse effects were recorded during that short trial. The study was nevertheless limited by its small sample, brief follow-up, and inclusion of patients with peripheral neuropathy from different causes.

Other trials produced potentially useful but preliminary results. Small studies of THC administered under the tongue or by inhalation found reductions in pain, while an eight-week trial involving women with fibromyalgia reported improvements in symptom scores and energy levels among those using THC-rich cannabis oil. These findings came from highly selected groups and, in some cases, assessed single-dose or short-term effects rather than sustained treatment.

The review’s safety conclusion requires caution. Although the five included trials recorded few serious problems, the authors acknowledged that they could not determine the long-term risks of cannabinoid treatment or its potential interactions with other medicines. Broader evidence reviews have found that cannabis-based products can cause dizziness, sedation, nausea, and treatment withdrawal because of side effects. The Agency for Healthcare Research and Quality’s living systematic review describes the evidence for chronic pain as low to moderate in strength and says that benefits are generally small and short term.

Evidence also differs sharply by product. THC-containing medicines and products with comparable THC-to-CBD ratios have shown some short-term benefit in certain neuropathic pain studies, while CBD-only products have not consistently improved pain outcomes. The National Center for Complementary and Integrative Health notes that cannabis and cannabinoids may provide modest relief for some chronic pain conditions, but side effects are more common than with placebo. CBD can also cause gastrointestinal symptoms, sleepiness, liver-related problems, and drug interactions.

These findings do not demonstrate that cannabinoids can replace opioids or other established treatments. The Centers for Disease Control and Prevention says that evidence for cannabis in most acute and chronic pain conditions remains limited and that more research is needed to determine how it compares with other pain-management options. Evidence that cannabis reduces opioid use is also inconclusive.

For patients with persistent neuropathic pain, cannabinoids may be worth discussing with a qualified clinician, particularly when standard treatments have not provided adequate relief or have caused unacceptable effects. Any decision should take into account the specific product, THC content, other medications, mental-health history, liver health, and local regulations. Larger, longer, and more diverse clinical trials are needed before the potential benefits and risks of cannabinoid therapy can be defined with confidence.